Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) Director George M. Jenkins purchased 4,000 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was bought at an average cost of $12.93 per share, with a total value of $51,720.00. Following the completion of the transaction, the director now owns 180,671 shares in the company, valued at approximately $2,336,076.03. This represents a 2.26 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.
Palvella Therapeutics Stock Performance
Shares of PVLA opened at $12.00 on Friday. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $22.32.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday. They issued an “overweight” rating on the stock.
Featured Articles
- Five stocks we like better than Palvella Therapeutics
- What is Forex and How Does it Work?
- Why Wall Street Sees Major Upside for PayPal Stock
- The 3 Best Blue-Chip Stocks to Buy Now
- Cintas Shares Slide: A Prime Opportunity to Buy the Dip
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Tempus AI: A Potential Double-Bagger After Recent Pullback
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
